Ola Snøve Named Epax CEO
Snøve, an investment director for Aker BioMarine ASA, replaces former Epax CEO Terje Bakken.
The board of directors at omega-3 concentrates supplier Epax AS (Oslo, Norway) named Ola Snøve its new CEO, the company announced Thursday.
Snøve, an investment director for Aker BioMarine ASA (Oslo), replaces Terje Bakken as Epax’s CEO, effective immediately. Aker is a joint venture between Epax and Lindsay Goldberg LLC (New York City).
With Snøve as its new CEO, Epax will continue its work in omega-3 concentrates and its development of a triglyceride-lowering drug.
Snøve’s background includes postdoctoral research at the Norwegian University of Science and Technology Department of Cancer Research and Molecular Biology and City of Hope’s Beckman Research Institute in California. He holds an MSc in mechanical engineering and a PhD in computer science from the Norwegian University of Science and Technology, and an MBA from INSEAD in France.
GC Rieber VivoMega uses AI platform from Intelecy to boost efficiency, quality, and sustainability
August 26th 2024According to the company’s announcement, the AI platform is able to identify real-time deviations or anomalies in GC Rieber VivoMega’s processing facilities and report them via a cloud-based, comprehensive, centralized system.
SourceOne Global Partners to distribute Qualitas Health’s microalgae omega-3 ingredient globally
August 15th 2024SourceOne Global Partners has announced a partnership with Qualitas Health Inc., (dba iwi life) to introduce the company’s trademarked AlmegaPL microalgae omega-3 ingredient to the global marketplace.
Recent animal study finds that Lysoveta may help reduce neonatal brain injury
July 17th 2024A recent animal study found that lysophosphatidylcholine (LPC)-bound omega-3 long-chain polyunsaturated fatty acids (LCPUFAs), marketed as Lysoveta by Aker BioMarine, protected against neonatal hypoxic-ischemic (HI) brain injury in mice.
